Eli Lilly
Eli Lilly and Co. is a global pharmaceutical powerhouse that has rapidly ascended to become one of the dual market leaders in the GLP-1 analogues space. The company’s innovative approach centers on dual receptor agonism, highlighted by its flagship injectable product, tirzepatide (branded as Mounjaro for type 2 diabetes and Zepbound for obesity). Tirzepatide, which acts as both a GLP-1 and GIP receptor agonist, has demonstrated superior efficacy in weight loss compared to earlier-generation GLP-1s, driving a significant surge in sales and market share. Beyond its established products, Eli Lilly is aggressively pursuing next-generation therapeutics. This includes the development of the oral small-molecule GLP-1 receptor agonist, orforglipron, which is expected to offer a convenient, needle-free alternative to injectable therapies and is currently in Phase 3 trials. Additionally, its pipeline features the investigational triple agonist, retatrutide, targeting GLP-1, GIP, and glucagon receptors for even greater metabolic control. Eli Lilly is simultaneously investing billions in manufacturing expansion to meet the overwhelming global demand, cementing its strategy to maintain long-term leadership through therapeutic innovation and accessibility.
Latest Market Research Report on GLP-1 Analogues Download PDF Brochure Now
Novo Nordisk
Novo Nordisk is a Danish multinational pharmaceutical company recognized as the historical and current market leader in diabetes and obesity care, a position largely built on its pioneering work with GLP-1 analogues. The company’s dominance stems from its flagship products based on semaglutide, marketed as Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. Novo Nordisk was the first to introduce a once-weekly injectable GLP-1 (semaglutide) and the first GLP-1 for weight loss (Saxenda), fundamentally reshaping the treatment landscape. Its R&D strategy focuses on optimizing drug delivery and developing combination therapies. Key pipeline candidates include CagriSema (a combination of semaglutide and cagrilintide) and advanced multi-agonists like the oral and subcutaneous formulations of amycretin, which targets three receptors—GLP-1, GIP, and glucagon—for enhanced clinical outcomes. By continuously expanding the indications for its GLP-1s, such as for cardiovascular risk reduction, and through major investments in manufacturing capacity, Novo Nordisk is working to secure its strategic position at the forefront of the surging global market.
Amgen
Amgen Inc. is a major American biopharmaceutical company that has emerged as a significant challenger in the GLP-1 analogue market with a distinct, next-generation approach. Unlike many competitors focused on small-molecule oral drugs, Amgen is advancing a unique antibody-based therapeutic called maridebart cafraglutide (formerly AMG 133, also known as MariTide). This molecule functions as a GLP-1 receptor agonist but also as a GIP receptor antagonist, a novel dual mechanism of action currently in Phase 3 clinical trials for obesity. MariTide’s design is hypothesized to offer sustained weight loss with an extended dosing interval, such as once a month, which would provide a critical advantage in patient convenience over the current weekly injectables. Amgen’s involvement in the GLP-1 space reflects its broader strategy of targeting high-impact metabolic diseases through cutting-edge protein engineering. By exploring this diversified, long-acting antibody program, Amgen is positioning itself to capture a significant segment of the future market for GLP-1-based therapeutics, with the potential to disrupt the dominance of existing weekly treatments.
Pfizer
Pfizer is one of the world’s preeminent pharmaceutical companies, strategically re-entering the GLP-1 analogue race with a focus on developing highly convenient, next-generation oral formulations. After facing setbacks with its initial oral candidate, danuglipron, the company executed the significant acquisition of clinical-stage biotech company Metsera, securing a robust pipeline of GLP-1 candidates. Pfizer’s strategy is heavily weighted toward small-molecule oral therapies, such as PF-07976016, a promising oral GIP analogue, with the explicit goal of overcoming the market’s reliance on injectables. The company aims to leverage its global commercial infrastructure and vast R&D resources to become a leading player in the rapidly expanding obesity and metabolic disorder treatment area. By investing in differentiated oral drugs and new molecular entities that target multiple incretin pathways, Pfizer is positioning itself to introduce products that offer greater patient accessibility and adherence, thereby challenging the market share currently held by injectable GLP-1 therapies.
Roche
F. Hoffmann-La Roche Ltd (Roche) is a major Swiss multinational healthcare company with a robust pharmaceuticals division that is actively building a significant pipeline in the GLP-1 analogue market. Roche has focused its efforts on acquiring promising early-stage assets and advancing its internal pipeline of novel obesity and diabetes candidates. Key to its strategy was the acquisition of Carmot Therapeutics, which brought a portfolio of incretin-based drugs, including dual GLP-1/GIP and triple agonists. The company is developing multiple obesity candidates, such as the oral pill CT-996, which are currently in Phase 2 trials. Additionally, Roche is collaborating with Zealand Pharma on petrelintide, an amylin analogue being developed as a monotherapy and in combination with GLP-1. Roche is expected to be a major entrant into the GLP-1 market around 2029, relying on a combination of strategic M&A and internal clinical advancements. Its deep expertise in drug development and global reach position it to become a significant challenger to the existing duopoly by launching differentiated, next-generation therapeutic agents.
Zealand Pharma
Zealand Pharma AS is a specialized Danish biotechnology company focusing on the discovery and development of innovative peptide-based medicines, including a strong portfolio of GLP-1 analogues and multi-agonists. The company’s core strength lies in its ability to engineer novel peptides that target multiple receptors for enhanced clinical effect. Zealand Pharma is a key pipeline player through its partnership with Boehringer Ingelheim on survodutide, a GLP-1/glucagon dual receptor agonist currently in Phase 3 trials for weight loss and MASH. It is also independently developing dapiglutide, a dual GLP-1/GLP-2 receptor agonist, and is collaborating with Roche on petrelintide, an amylin analogue. These candidates aim to provide superior efficacy and address comorbidities associated with metabolic disease, such as inflammation and liver health. Zealand Pharma primarily serves as an engine of innovation, licensing its most advanced candidates to larger pharmaceutical companies or co-developing them, thereby playing a critical role in pushing the boundaries of the next-generation GLP-1 therapeutics market.
Altimmune
Altimmune is a US-based clinical-stage biopharmaceutical company specializing in the development of peptide-based therapeutics for obesity and liver disease. Its lead program in the GLP-1 space is pemvidutide, a distinct GLP-1/glucagon dual receptor agonist. This approach aims to differentiate itself from single-agonist GLP-1 drugs and dual GLP-1/GIP agonists by uniquely targeting the glucagon receptor alongside GLP-1. The mechanism is designed not only to reduce appetite (via GLP-1) but also to increase energy expenditure (via glucagon), which is theorized to lead to more favorable changes in body composition and a greater reduction in fat mass. Pemvidutide is currently in late-stage clinical trials for the treatment of obesity and MASH (metabolic dysfunction-associated steatohepatitis). By focusing on a differentiated mechanism of action with the potential for best-in-class efficacy for weight loss and liver fat reduction, Altimmune is positioning itself as a key emerging competitor poised to enter the rapidly evolving market for advanced metabolic therapeutics.
Viking Therapeutics
Viking Therapeutics is a clinical-stage biopharmaceutical company based in California, with a strong focus on developing novel therapies for metabolic and endocrine disorders. The company has gained significant attention in the GLP-1 analogue market with its lead pipeline candidate, VK2735. VK2735 is a dual agonist targeting both the Glucagon-like Peptide-1 (GLP-1) and Glucose-dependent Insulinotropic Polypeptide (GIP) receptors. This mechanism mirrors the highly successful dual-agonist strategy used by a market leader. VK2735 is being developed in both injectable and oral formulations, with its injectable version having shown highly promising weight loss data in early-stage clinical trials. Viking’s strategy is to rapidly advance its differentiated dual-agonist program to provide a powerful and highly efficacious therapeutic option in a landscape dominated by a few large players. Its strong clinical results have established it as one of the most compelling pure-play biotech companies in the obesity sector and a potential acquisition target for larger pharmaceutical firms looking to enter or bolster their GLP-1 portfolio.
Sanofi
Sanofi is a major French multinational pharmaceutical company with a commercialized presence in the GLP-1 analogue market, primarily through its combination drug, Soliqua. Soliqua is a fixed-ratio combination of basal insulin glargine and the GLP-1 receptor agonist lixisenatide, specifically indicated for the treatment of adults with type 2 diabetes. This product is a practical solution that simplifies diabetes management by combining two complementary treatments into a single daily injection, thereby offering sustained glycemic control with a reduced risk of weight gain compared to insulin monotherapy. While Sanofi is strategically reorienting its primary R&D focus toward other therapeutic areas like immunology, it maintains a global footprint in diabetes care. The company leverages its robust supply chain infrastructure to ensure wide geographic distribution and accessibility, notably expanding the reach of its GLP-1-based solutions in emerging markets. Sanofi’s role, therefore, is crucial in delivering fixed-combination GLP-1 therapies for diabetes management on a global scale.
Hanmi Pharmaceutical
Hanmi Pharmaceutical is a prominent South Korean pharmaceutical company recognized for its extensive R&D efforts in developing multi-receptor agonists, positioning it as a key player in the next generation of GLP-1 analogues. The company has a robust pipeline featuring several investigational drugs, most notably HM15275, a highly advanced tri-agonist that targets GLP-1, GIP, and glucagon receptors. This triple-action approach is designed to maximize therapeutic efficacy for both obesity and related metabolic conditions, such as MASH (Metabolic dysfunction-associated steatohepatitis). Hanmi has also been an active patent filer in the GLP-1 space, underscoring its long-term commitment to the therapeutic area. Furthermore, its pipeline includes other multi-receptor agonists like efpeglenatide, efinopegdutide, and efocipegtrutide, which are advancing through late-stage clinical development. By focusing on highly complex, multi-receptor targeting peptides, Hanmi is looking to compete with global pharmaceutical giants by offering differentiated and potentially superior clinical profiles for patients with challenging metabolic diseases.
Latest Market Research Report on GLP-1 Analogues Download PDF Brochure Now